Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
04 2021
Historique:
received: 19 09 2020
revised: 12 11 2020
accepted: 17 11 2020
pubmed: 3 1 2021
medline: 1 5 2021
entrez: 2 1 2021
Statut: ppublish

Résumé

Pancreatoduodenectomies at high risk for clinically relevant pancreatic fistula are uncommon, yet intimidating, situations. In such scenarios, the impact of individual surgeon experience on outcomes is poorly understood. The fistula risk score was applied to identify high-risk patients (fistula risk score 7-10) from 7,706 pancreatoduodenectomies performed at 18 international institutions (2003-2020). For each case, surgeon pancreatoduodenectomy career volume and years of practice were linked to intraoperative fistula mitigation strategy adoption and outcomes. Consequently, best operative approaches for clinically relevant pancreatic fistula prevention and best performer profiles were identified through multivariable analysis models. Eight hundred and thirty high-risk pancreatoduodenectomies, performed by 64 surgeons, displayed an overall clinically relevant pancreatic fistula rate of 33.7%. Clinically relevant pancreatic fistula rates decreased with escalating surgeon career pancreatoduodenectomy (-49.7%) and career length (-41.2%; both P < .001), as did transfusion and reoperation rates, postoperative morbidity index, and duration of stay. Great experience (≥400 pancreatoduodenectomies performed or ≥21-year-long career) was a significant predictor of clinically relevant pancreatic fistula prevention (odds ratio 0.52, 95% confidence interval 0.35-0.76) and was more often associated with pancreatojejunostomy reconstruction and prophylactic octreotide omission, which were both independently associated with clinically relevant pancreatic fistula reduction. A risk-adjusted performance analysis also correlated with experience. Moreover, minimizing blood loss (≤400 mL) significantly contributed to clinically relevant pancreatic fistula prevention (odds ratio 0.40, 95% confidence interval 0.22-0.74). Surgeon experience is a key contributor to achieve better outcomes after high-risk pancreatoduodenectomy. Surgeons can improve their performance in these challenging situations by employing pancreatojejunostomy reconstruction, omitting prophylactic octreotide, and minimizing blood loss.

Sections du résumé

BACKGROUND
Pancreatoduodenectomies at high risk for clinically relevant pancreatic fistula are uncommon, yet intimidating, situations. In such scenarios, the impact of individual surgeon experience on outcomes is poorly understood.
METHODS
The fistula risk score was applied to identify high-risk patients (fistula risk score 7-10) from 7,706 pancreatoduodenectomies performed at 18 international institutions (2003-2020). For each case, surgeon pancreatoduodenectomy career volume and years of practice were linked to intraoperative fistula mitigation strategy adoption and outcomes. Consequently, best operative approaches for clinically relevant pancreatic fistula prevention and best performer profiles were identified through multivariable analysis models.
RESULTS
Eight hundred and thirty high-risk pancreatoduodenectomies, performed by 64 surgeons, displayed an overall clinically relevant pancreatic fistula rate of 33.7%. Clinically relevant pancreatic fistula rates decreased with escalating surgeon career pancreatoduodenectomy (-49.7%) and career length (-41.2%; both P < .001), as did transfusion and reoperation rates, postoperative morbidity index, and duration of stay. Great experience (≥400 pancreatoduodenectomies performed or ≥21-year-long career) was a significant predictor of clinically relevant pancreatic fistula prevention (odds ratio 0.52, 95% confidence interval 0.35-0.76) and was more often associated with pancreatojejunostomy reconstruction and prophylactic octreotide omission, which were both independently associated with clinically relevant pancreatic fistula reduction. A risk-adjusted performance analysis also correlated with experience. Moreover, minimizing blood loss (≤400 mL) significantly contributed to clinically relevant pancreatic fistula prevention (odds ratio 0.40, 95% confidence interval 0.22-0.74).
CONCLUSION
Surgeon experience is a key contributor to achieve better outcomes after high-risk pancreatoduodenectomy. Surgeons can improve their performance in these challenging situations by employing pancreatojejunostomy reconstruction, omitting prophylactic octreotide, and minimizing blood loss.

Identifiants

pubmed: 33386129
pii: S0039-6060(20)30807-2
doi: 10.1016/j.surg.2020.11.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

708-720

Investigateurs

William E Fisher (WE)
George Van Buren (G)
Mark P Callery (MP)
Tara S Kent (TS)
Wande B Pratt (WB)
Charles M Vollmer (CM)
Ammara A Watkins (AA)
Michael G House (MG)
Joal D Beane (JD)
Adam C Berger (AC)
Christopher L Wolfgang (CL)
Ammar A Javed (AA)
Katherine E Poruk (KE)
Kevin C Soares (KC)
Vicente Valero (V)
Carlos Fernandez-Del Castillo (C)
Zhi V Fong (ZV)
Horacio J Asbun (HJ)
John A Stauffer (JA)
Mark P Bloomston (MP)
Mary E Dilhoff (ME)
Ericka N Haverick (EN)
Carl R Schmidt (CR)
John D Christein (JD)
Robert H Hollis (RH)
Chad G Ball (CG)
Elijah Dixon (E)
Steven J Hughes (SJ)
Charles M Vollmer (CM)
Jeffrey A Drebin (JA)
Brett Ecker (B)
Russell Lewis (R)
Matthew McMillan (M)
Benjamin Miller (B)
Priya Puri (P)
Thomas Seykora (T)
Michael J Sprys (MJ)
Amer H Zureikat (AH)
Stacy J Kowalsky (SJ)
Stephen W Behrman (SW)
Claudio Bassi (C)
Fabio Casciani (F)
Laura Maggino (L)
Giuseppe Malleo (G)
Roberto Salvia (R)
Giulia Savegnago (G)
Lorenzo Cinelli (L)
Massimo Falconi (M)
Stefano Partelli (S)
Euan J Dickson (EJ)
Nigel B Jamieson (NB)
Lavanniya K P Velu (LKP)
Ronald R Salem (RR)
John W Kunstman (JW)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Fabio Casciani (F)

Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Unit of General and Pancreatic Surgery, The Pancreas Institute, University of Verona, Italy.

Maxwell T Trudeau (MT)

Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

Horacio J Asbun (HJ)

Department of Surgery, Mayo Clinic, Jacksonville, FL.

Chad G Ball (CG)

Department of Surgery, University of Calgary, Canada.

Claudio Bassi (C)

Unit of General and Pancreatic Surgery, The Pancreas Institute, University of Verona, Italy.

Stephen W Behrman (SW)

The University of Tennessee Health Science Center, Memphis, TN.

Adam C Berger (AC)

Department of Surgery, Jefferson Medical College, Philadelphia, PA.

Mark P Bloomston (MP)

Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.

Mark P Callery (MP)

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

John D Christein (JD)

Department of Surgery, University of Alabama at Birmingham School of Medicine, AL.

Massimo Falconi (M)

IRCSS San Raffaele Scientific Institute, Milan, Italy.

Carlos Fernandez-Del Castillo (C)

Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Mary E Dillhoff (ME)

Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.

Euan J Dickson (EJ)

West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, United Kingdom.

Elijah Dixon (E)

Department of Surgery, University of Calgary, Canada.

William E Fisher (WE)

Department of Surgery, Baylor College of Medicine, Houston, TX.

Michael G House (MG)

Department of Surgery, Indiana University School of Medicine, Indianapolis, IN.

Steven J Hughes (SJ)

Department of Surgery, University of Florida College of Medicine, Gainesville, FL.

Tara S Kent (TS)

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

Giuseppe Malleo (G)

Unit of General and Pancreatic Surgery, The Pancreas Institute, University of Verona, Italy.

Stefano Partelli (S)

IRCSS San Raffaele Scientific Institute, Milan, Italy.

Ronald R Salem (RR)

Department of Surgery, Yale School of Medicine, New Haven, CT.

John A Stauffer (JA)

Department of Surgery, Mayo Clinic, Jacksonville, FL.

Christopher L Wolfgang (CL)

Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD.

Amer H Zureikat (AH)

Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.

Charles M Vollmer (CM)

Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Electronic address: Charles.Vollmer@uphs.upenn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH